Patrick Daly, MD
Internal Medicine · Dallas, TXNPI 1063480853
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,257 of the $7,257 with a category attached, or 72.4%. 33 manufacturers reported payments, led by Johnson & Johnson at 32.6% of the total. Reporting peaked in 2019 at $3,036 and has fallen 98.5% since, to $46 in 2022. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 320 payments — averaging $22.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Viiv Healthcare Company$1K
- Merck$650
- Gilead$387
- Novo Nordisk$319
- Sanofi-aventis U.S. LLC$293
- plus $2K from 27 others
What the payments were for
- Consulting fees$1,62522%
- Speaking & faculty fees$2754%
- Food & beverage$5,25772%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 57 | $2,366 |
| Viiv Healthcare Company | 51 | $1,182 |
| Merck | 49 | $650 |
| Gilead | 20 | $387 |
| Novo Nordisk | 23 | $319 |
| Sanofi-aventis U.S. LLC | 2 | $293 |
| Pfizer | 16 | $228 |
| Janssen Products, LP | 2 | $225 |
| Theratechnologies Inc. | 11 | $193 |
| EMD Serono, Inc. | 10 | $190 |
| AstraZeneca | 9 | $137 |
| AbbVie(2 entities) | 5 | $122 |
| GSK | 7 | $111 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $97 |
| Aytu Biopharma, Inc. | 6 | $93 |
| Lilly USA, LLC | 6 | $90 |
| Boehringer Ingelheim | 5 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $76 |
| Kowa Pharmaceuticals America, Inc. | 5 | $62 |
| Ironwood Pharmaceuticals, Inc | 3 | $49 |
| Organon | 4 | $46 |
| Janssen Scientific Affairs, LLC | 2 | $28 |
| Antares Pharma, Inc. | 2 | $26 |
| Jazz Pharmaceuticals Inc. | 2 | $26 |
| Mannkind Corporation | 2 | $25 |
| Amarin Pharma, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $21 |
| Eisai Inc. | 1 | $21 |
| Napo Pharmaceuticals Inc | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Therapeuticsmd, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$1,625
- SOLIQUA 100/33$275
- Symtuza$125
- DOVATO$108
How this compares
$7,257 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 95 | $111,866 |
| JanuviaSitagliptin Phosphate | 45 | $64,850 |
| TrulicityDulaglutide | 29 | $28,237 |
| EliquisApixaban | 21 | $24,440 |
| XareltoRivaroxaban | 25 | $24,319 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $17,470 |
| TradjentaLinagliptin | 11 | $16,030 |
| FarxigaDapagliflozin Propanediol | 11 | $15,474 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 43 | $12,658 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 107 | $11,738 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $7,393 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 24 | $5,107 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 18 | $3,212 |
| Levemir FlexpenInsulin Detemir | 15 | $2,748 |
| Atorvastatin Calcium | 362 | $2,733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $89 | $127,896106 claims |
| MerckJanuvia, Janumet | $650 | $82,32061 claims |
| Lilly USA, LLCTrulicity | $90 | $28,23729 claims |
| PfizerEliquis | $228 | $24,44021 claims |
| Johnson & JohnsonXarelto | $2,366 | $24,31925 claims |
| AstraZenecaFarxiga | $137 | $15,47411 claims |
| GSKShingrix | $111 | $5,10724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Dallas
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Han SchmidlyDallas$465K
- Athica VatanapradithDallas$164K
- Nicholaos BellosDallas$113K
- Steven HeldDallas$65K
- Amit VermaDallas$53K
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Mohammed Al-NajjarEl Paso$586K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.